Difference of gut microbiota between patients with negative and positive HBeAg in chronic hepatitis B and the effect of tenofovir alafenamide on intestinal flora
BackgroundSevere liver diseases, such as liver fibrosis, cirrhosis, and liver cancer, are mainly caused by hepatitis B virus (HBV). This study investigated the differences between gut microbiota in HBeAg-positive and negative groups of patients with chronic hepatitis B (CHB) and investigated the eff...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmicb.2023.1232180/full |
| _version_ | 1797635342898036736 |
|---|---|
| author | Jianfei Long Jingru Gong Han Zhu Xiaolin Liu Ling Li Bicui Chen Hongyan Ren Chao Liu Huiping Lu Jiming Zhang Jiming Zhang Jiming Zhang Bin Wang Bin Wang |
| author_facet | Jianfei Long Jingru Gong Han Zhu Xiaolin Liu Ling Li Bicui Chen Hongyan Ren Chao Liu Huiping Lu Jiming Zhang Jiming Zhang Jiming Zhang Bin Wang Bin Wang |
| author_sort | Jianfei Long |
| collection | DOAJ |
| description | BackgroundSevere liver diseases, such as liver fibrosis, cirrhosis, and liver cancer, are mainly caused by hepatitis B virus (HBV). This study investigated the differences between gut microbiota in HBeAg-positive and negative groups of patients with chronic hepatitis B (CHB) and investigated the effect of tenofovir alafenamide (TAF) on gut microbiota.MethodsThis prospective study included patients with CHB not taking nucleoside antivirals (No-NAs group, n = 95) and those taking TAF (TAF group, n = 60). We divided CHB patients into two groups according to the HBeAg status of the subjects on the day of data collection. Phase 1 are HBeAg-negative patients and phase 2 are HBeAg-positive patients. We investigated the improvement of clinical symptoms by TAF, as well as differences in gut microbiota between different groups by 16S rRNA high-throughput sequencing.ResultsGut microbiota demonstrated significant differences between patients with HBeAg-positive and -negative CHB. Both the No-NAs and TAF Phase 2 subgroups demonstrated significantly increased microbiota richness and diversity, showing greater heterogeneity. Additionally, the Phase 2 subgroup exhibited a low abundance of pathways associated with glucose metabolism and amino acid metabolism. The TAF group demonstrated a significantly decreased HBV load, alanine aminotransferase, and aspartate aminotransferase and a significant increase in prealbumin compared with the No-NAs group. No significant difference was found in uric acid, creatinine, blood calcium, inorganic phosphorus, eGFR, and β2-microglobulin concentrations between the two groups. Additionally, the urea level in the TAF group was significantly lower than that in the No-NAs group, but with no significant effect on other indicators such as eGFR and β2-microglobulin.ConclusionThis study revealed significant differences in gut microbiota composition and function between patients with HBeAg-positive and -negative CHB. |
| first_indexed | 2024-03-11T12:19:45Z |
| format | Article |
| id | doaj.art-74590ff793b74fad8c99f08357d500f4 |
| institution | Directory Open Access Journal |
| issn | 1664-302X |
| language | English |
| last_indexed | 2024-03-11T12:19:45Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Microbiology |
| spelling | doaj.art-74590ff793b74fad8c99f08357d500f42023-11-07T03:28:11ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2023-09-011410.3389/fmicb.2023.12321801232180Difference of gut microbiota between patients with negative and positive HBeAg in chronic hepatitis B and the effect of tenofovir alafenamide on intestinal floraJianfei Long0Jingru Gong1Han Zhu2Xiaolin Liu3Ling Li4Bicui Chen5Hongyan Ren6Chao Liu7Huiping Lu8Jiming Zhang9Jiming Zhang10Jiming Zhang11Bin Wang12Bin Wang13Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, ChinaDepartment of Pharmacy, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, ChinaDepartment of Pharmacy, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, ChinaDepartment of Pharmacy, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, ChinaDepartment of Pharmacy, Jing’an District Central Hospital, Fudan University, Shanghai, ChinaDepartment of Pharmacy, Huashan Hospital, Fudan University, Shanghai, ChinaShanghai Mobio Biomedical Technology Co., Ltd., Shanghai, ChinaShanghai Mobio Biomedical Technology Co., Ltd., Shanghai, ChinaDepartment of Pharmacy, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, ChinaDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, ChinaShanghai Institute of Infectious Diseases and Biosecurity, Key Laboratory of Medical Molecular Virology (MOE/MOH), Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Infectious Diseases, Jing’An Branch of Huashan Hospital, Fudan University, Shanghai, ChinaDepartment of Pharmacy, Huashan Hospital, Fudan University, Shanghai, ChinaDepartment of Pharmacy, Jing’an District Central Hospital, Fudan University, Shanghai, ChinaBackgroundSevere liver diseases, such as liver fibrosis, cirrhosis, and liver cancer, are mainly caused by hepatitis B virus (HBV). This study investigated the differences between gut microbiota in HBeAg-positive and negative groups of patients with chronic hepatitis B (CHB) and investigated the effect of tenofovir alafenamide (TAF) on gut microbiota.MethodsThis prospective study included patients with CHB not taking nucleoside antivirals (No-NAs group, n = 95) and those taking TAF (TAF group, n = 60). We divided CHB patients into two groups according to the HBeAg status of the subjects on the day of data collection. Phase 1 are HBeAg-negative patients and phase 2 are HBeAg-positive patients. We investigated the improvement of clinical symptoms by TAF, as well as differences in gut microbiota between different groups by 16S rRNA high-throughput sequencing.ResultsGut microbiota demonstrated significant differences between patients with HBeAg-positive and -negative CHB. Both the No-NAs and TAF Phase 2 subgroups demonstrated significantly increased microbiota richness and diversity, showing greater heterogeneity. Additionally, the Phase 2 subgroup exhibited a low abundance of pathways associated with glucose metabolism and amino acid metabolism. The TAF group demonstrated a significantly decreased HBV load, alanine aminotransferase, and aspartate aminotransferase and a significant increase in prealbumin compared with the No-NAs group. No significant difference was found in uric acid, creatinine, blood calcium, inorganic phosphorus, eGFR, and β2-microglobulin concentrations between the two groups. Additionally, the urea level in the TAF group was significantly lower than that in the No-NAs group, but with no significant effect on other indicators such as eGFR and β2-microglobulin.ConclusionThis study revealed significant differences in gut microbiota composition and function between patients with HBeAg-positive and -negative CHB.https://www.frontiersin.org/articles/10.3389/fmicb.2023.1232180/fullhepatitis B virusHBeAgHBsAgtenofovir alafenamidegut microbiota |
| spellingShingle | Jianfei Long Jingru Gong Han Zhu Xiaolin Liu Ling Li Bicui Chen Hongyan Ren Chao Liu Huiping Lu Jiming Zhang Jiming Zhang Jiming Zhang Bin Wang Bin Wang Difference of gut microbiota between patients with negative and positive HBeAg in chronic hepatitis B and the effect of tenofovir alafenamide on intestinal flora Frontiers in Microbiology hepatitis B virus HBeAg HBsAg tenofovir alafenamide gut microbiota |
| title | Difference of gut microbiota between patients with negative and positive HBeAg in chronic hepatitis B and the effect of tenofovir alafenamide on intestinal flora |
| title_full | Difference of gut microbiota between patients with negative and positive HBeAg in chronic hepatitis B and the effect of tenofovir alafenamide on intestinal flora |
| title_fullStr | Difference of gut microbiota between patients with negative and positive HBeAg in chronic hepatitis B and the effect of tenofovir alafenamide on intestinal flora |
| title_full_unstemmed | Difference of gut microbiota between patients with negative and positive HBeAg in chronic hepatitis B and the effect of tenofovir alafenamide on intestinal flora |
| title_short | Difference of gut microbiota between patients with negative and positive HBeAg in chronic hepatitis B and the effect of tenofovir alafenamide on intestinal flora |
| title_sort | difference of gut microbiota between patients with negative and positive hbeag in chronic hepatitis b and the effect of tenofovir alafenamide on intestinal flora |
| topic | hepatitis B virus HBeAg HBsAg tenofovir alafenamide gut microbiota |
| url | https://www.frontiersin.org/articles/10.3389/fmicb.2023.1232180/full |
| work_keys_str_mv | AT jianfeilong differenceofgutmicrobiotabetweenpatientswithnegativeandpositivehbeaginchronichepatitisbandtheeffectoftenofoviralafenamideonintestinalflora AT jingrugong differenceofgutmicrobiotabetweenpatientswithnegativeandpositivehbeaginchronichepatitisbandtheeffectoftenofoviralafenamideonintestinalflora AT hanzhu differenceofgutmicrobiotabetweenpatientswithnegativeandpositivehbeaginchronichepatitisbandtheeffectoftenofoviralafenamideonintestinalflora AT xiaolinliu differenceofgutmicrobiotabetweenpatientswithnegativeandpositivehbeaginchronichepatitisbandtheeffectoftenofoviralafenamideonintestinalflora AT lingli differenceofgutmicrobiotabetweenpatientswithnegativeandpositivehbeaginchronichepatitisbandtheeffectoftenofoviralafenamideonintestinalflora AT bicuichen differenceofgutmicrobiotabetweenpatientswithnegativeandpositivehbeaginchronichepatitisbandtheeffectoftenofoviralafenamideonintestinalflora AT hongyanren differenceofgutmicrobiotabetweenpatientswithnegativeandpositivehbeaginchronichepatitisbandtheeffectoftenofoviralafenamideonintestinalflora AT chaoliu differenceofgutmicrobiotabetweenpatientswithnegativeandpositivehbeaginchronichepatitisbandtheeffectoftenofoviralafenamideonintestinalflora AT huipinglu differenceofgutmicrobiotabetweenpatientswithnegativeandpositivehbeaginchronichepatitisbandtheeffectoftenofoviralafenamideonintestinalflora AT jimingzhang differenceofgutmicrobiotabetweenpatientswithnegativeandpositivehbeaginchronichepatitisbandtheeffectoftenofoviralafenamideonintestinalflora AT jimingzhang differenceofgutmicrobiotabetweenpatientswithnegativeandpositivehbeaginchronichepatitisbandtheeffectoftenofoviralafenamideonintestinalflora AT jimingzhang differenceofgutmicrobiotabetweenpatientswithnegativeandpositivehbeaginchronichepatitisbandtheeffectoftenofoviralafenamideonintestinalflora AT binwang differenceofgutmicrobiotabetweenpatientswithnegativeandpositivehbeaginchronichepatitisbandtheeffectoftenofoviralafenamideonintestinalflora AT binwang differenceofgutmicrobiotabetweenpatientswithnegativeandpositivehbeaginchronichepatitisbandtheeffectoftenofoviralafenamideonintestinalflora |